Voice features linked to pulmonary hypertension and heart disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study enrolling adults referred for clinically indicated diagnostic echocardiograms at Mayo Clinic Rochester. Investigators will collect brief voice recordings and compare signal characteristics with echocardiography findings and clinical data to look for patterns associated with presence and severity of pulmonary hypertension and other cardiovascular disease. Patients with known voice disorders are excluded to avoid confounding voice-pathology effects. The goal is to identify noninvasive voice-based markers that correlate with established imaging measures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All individuals who present for a routine elective, clinically indicated, diagnostic echocardiogram at the echocardiography laboratory at Mayo Clinic
* All individuals who have had a clinically indicated, diagnostic echocardiogram at the echocardiography lab at Mayo Clinic before a scheduled procedure in the cardiac catheterization lab at Mayo Clinic
* All individuals who have had a clinically indicated diagnostic echocardiogram at the echocardiography lab at Mayo Clinic and have an appointment in any CV outpatient clinic.

Exclusion Criteria:

* Known history of voice disorder either primary or secondary to neuromuscular or other pathology
* Patients under the age of 18 years

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Amir Lerman, M.D. — Mayo Clinic
• Study coordinator: Diana Albers
• Email: albers.diana2@mayo.edu
• Phone: 507-255-6884

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD

  This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 13 sites Phase 2 Pulmovant, Inc. · Santa Barbara, California and 12 other locations · NCT07333183

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

• Evaluating a heart pump for patients with advanced heart failure

  This study is testing if a heart pump can help people with advanced heart failure feel better compared to standard medication, while also checking if certain pressure readings can help find the right patients for this treatment.

  Recruiting at 68 sites Abbott Medical Devices · Phoenix, Arizona and 69 other locations · NCT06526195

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.